Loading
A phase 1 trial of HP518 run by Hinova Pharmaceuticals Aus Pty Ltd, completed.
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05252364 by Hinova Pharmaceuticals Aus Pty Ltd, with 22 participants enrolled, started 2021-12-14. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: HP518 - Dose Escalation and HP518 - Dose expansion.
Shares HP518, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/